Christopher W. Cain - Jun 7, 2022 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Role: Director
Signature: /s/ Evan D. Kearns, Attorney-in-Fact
Stock symbol: COGT
Transactions as of: Jun 7, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/9/2022, 05:09 PM
Next filing: Jun 8, 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	COGT	Stock Option (Right to Buy)	Award	$0	+30.7K		$0.00	30.7K	Jun 7, 2022	Common Stock	30.7K	$4.59	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This annual stock option award was made on the date of the 2022 Annual Meeting of Stockholders pursuant to the company's Non-Employee Director Compensation Program and shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders.

Remarks:

Exhibit 24 - Power of Attorney Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.